Table 2.

Studies reflecting cisplatin-associated hearing loss in adults.

Study	Country	Type of study	Audiological tests conducted	Patient population	Number of patients who developed ototoxicity
Malgonde et al. [47]	India	Prospective	Pure tone audiometry (frequencies not specified) and short increment sensitivity index test	34 patients with head and neck cancers receiving cisplatin containing chemotherapy and concomitant radiation therapy	34 (100%)
Whitehorn et al. [48]	South Africa	Retrospective cross-sectional	Air (0.25–8 kHz) and bone conduction pure tone audiometry	107 patients receiving cisplatin containing chemotherapy, irrespective of the type of the cancer	59 (55.1%)
Nitz et al. [49]	Germany	Prospective longitudinal trinational population-based	Air (0.125–8 kHz) and bone conduction pure tone audiometry	1 patient with soft-tissue sarcoma and 16 with osteosarcoma, receiving cisplatin and/or carboplatin containing chemotherapy	6 (35.3%)
Arora et al. [8]	India	Prospective, randomized, observational	Pure tone air (0.25–16 kHz) and bone conduction audiometry Results are reflective of frequencies 4 to 16 kHz.	57 patients receiving cisplatin containing chemotherapy:	—
				10 patients (low dose group, carcinoma of the larynx)	6 (60%)
				35 patients (middle dose group, head and neck cancers, carcinoma of the cervix)	35 (100%)
				12 patients (high dose group, carcinoma of the lung and carcinoma of the testis)	12 (100%)
Dell'Aringa et al. [50]	Brazil	Case series	Tympanometry, acoustic reflex threshold testing, distortion product otoacoustic emissions (DPOAEs), air (0.25–8 kHz) and bone conduction pure tone audiometry, speech audiometry	17 patients with extracranial head and neck cancers receiving cisplatin containing chemotherapy and concomitant radiation therapy	12 (70.5%), left ears; 11 (64.7%), right ears
Schultz et al. [51]	Brazil	Prospective	Full audiometric evaluations, with only air (0.25–8 kHz) and bone conduction pure tone audiometry thresholds computed	31 patients receiving cisplatin containing chemotherapy, irrespective of the type of cancer	12 (38%), NCI criteria; 19 (65%), Brock et al.'s criteria; 17 (54%), ASHA criteria; 9 (29%), David and Silverman's criteria
Zuur et al. [52]	The Netherlands	Prospective	Air (0.125–16 kHz) and bone conduction pure tone audiometry	60 patients with locally advanced head and neck cancer, receiving cisplatin containing chemotherapy and concomitant radiation therapy	19 (31%), up to 8 kHz; 28 (47%), up to 16 kHz
Dutta et al. [36]	India	Prospective	Pure tone audiometry (frequencies not specified)	60 patients receiving cisplatin containing chemotherapy, type of cancer not indicated	9 (15%)
				51, low dose group	6 (12%)
				9, high dose group	3 (33%)
Strumberg et al. [53]	Germany	Retrospective	Pure tone air (0.125–12 kHz) and bone conduction audiometry, transient evoked otoacoustic emissions test (TEOAE)	32 patients with testicular cancer receiving cisplatin containing chemotherapy	21 (70%)
Nagy et al. [54]	USA	Retrospective	Tympanometry, air (0.25–8 KHz) conduction pure tone audiometry	53 patients with oesophageal, lung, or head and neck cancer receiving cisplatin containing chemotherapy and concomitant radiation therapy (only for head and neck cancer)	19 (36%)
Bokemeyer et al. [35]	Germany	Retrospective	Pure tone air (0.5–8 kHz) and bone audiometry	86 patients with testicular cancer receiving cisplatin containing chemotherapy	57 (66%)
Waters et al. [32]	Canada	Retrospective	Pure tone air (0.25–8 kHz) and bone conduction audiometry, immittance audiometry, and speech audiometry	60 patients with advanced ovarian carcinomas receiving cisplatin containing chemotherapy
				39, low dose, short treatment (25 from LDE group and 14 new cases after treatment modification)	6 (15%)
				8, low dose, blocks	0 (0%)
				25, low dose, extended treatment	9 (36%)
				13, high dose, short treatment	12 (92%)